Search the Newsreel

IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of IDEXX Laboratories Inc (IDXX), focusing on its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock has a momentum score of 3.37, trading between a resistance of 605.29 and support …

IDEXX (IDXX) Stock Looks Fair On Cash Flow But Rich On Earnings

Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?

IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected …

Idexx Laboratories (IDXX) Receives a Buy from Barclays

Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating

Barclays has updated its price target for IDEXX Laboratories (IDXX), lowering it to $710 from the previous $800. Despite this adjustment, the firm has decided to maintain its Overweight rating on the stock. This indicates a continued positive outlook on the company's performance, even …

IDEXX launches in-clinic cardiac test for cats and dogs

IDEXX Laboratories Inc. has launched the Catalyst proBNP Test, an in-clinic diagnostic tool for heart disease in cats and dogs. This test measures the NT-proBNP biomarker, providing rapid quantitative results to veterinarians for screening, diagnosis, and monitoring of cardiac conditions. The test will be …

IDEXX Laboratories (IDXX) Unveils First Dual Species Cardiac Test For Dogs And Cats

IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors

IDEXX Laboratories Inc. (IDXX) stock fell 1.53% on Tuesday, closing at $586.64, despite a general downturn in the stock market. The S&P 500 Index and Dow Jones Industrial Average also saw declines of 0.32% and 0.34%, respectively. The company's stock is now 23.81% below …

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, …

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories, Inc. has launched the Catalyst™ proBNP Test, a new dual-species, in-clinic test for NT-proBNP, expanding its cardiac diagnostic capabilities. This test provides rapid, accurate quantitative cardiac assessment for cats and dogs directly at the point of care, addressing a significant need in …

IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment

IDEXX Laboratories has introduced the Catalyst proBNP Test, designed for in-clinic assessment of cardiac disease in animals. This launch is expected to enhance veterinary diagnostics by providing rapid and accurate results. The company, a leader in veterinary diagnostics, continues to innovate in the animal …

IDEXX Test Brings Heart-Disease Results for Cats and Dogs in Minutes

IDEXX Laboratories has launched the Catalyst™ proBNP Test, a new in-clinic diagnostic tool for heart disease in cats and dogs. This dual-species test provides quantitative NT-proBNP results in minutes, allowing veterinarians to assess cardiac health and make informed treatment decisions faster. The test expands …

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Inc. (IDXX) saw its stock rally by 1.55% to $595.76 on Monday, performing strongly despite an overall poor trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both experienced declines. IDEXX Laboratories Inc. is currently trading …

Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX

Seilern Investment Management Ltd increased its stake in IDEXX Laboratories, Inc. by 20.7% in the second quarter, purchasing an additional 16,729 shares. The firm now holds 97,560 shares valued at approximately $51.4 million, making IDEXX its fifth-largest position. IDEXX Laboratories reported strong quarterly results, …

IDEXX Laboratories Inc (HAM:IX1) Stock Price & 30 Year Financial Data

This article provides comprehensive 30-year financial data for IDEXX Laboratories Inc (HAM:IX1), including growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow. It details key financial metrics such as Market Cap, Enterprise Value, PE Ratio, PB Ratio, and GF Score, offering an …

IDEXX Labs posts 9% organic growth, raises EPS forecast, driven by global diagnostic expansion.

IDEXX Laboratories reported a 9% organic revenue growth in Q2 2026 and has subsequently increased its EPS guidance to $14.69–14.94, driven by strong demand for its veterinary diagnostic products. While growth in the US market is decelerating, significant long-term potential is seen in international …

IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history

This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, key financial statistics, historical performance, and analyst ratings. It details the company's operations in animal diagnostics, water quality, and veterinary software, and compares its performance to benchmarks like …

Aurora Investment Managers LLC. Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Aurora Investment Managers LLC. has acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX), purchasing 4,638 shares valued at approximately $2.44 million. This investment makes IDEXX Laboratories the 21st largest position in Aurora Investment Managers' portfolio, representing 1.5% of its total investments. The article …

Noticias de acciones de IDEXX Laboratories Inc (IDXX)

What Does IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Indicate?

This article analyzes IDEXX Laboratories, Inc.'s stock price movements and valuation, utilizing a discounted cash flow (DCF) model to estimate its intrinsic value. It suggests the stock may be trading below its fair value, indicating potential for growth despite a recent price decline.

IDEXX Laboratories Inc (IDXX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter.

How IDEXX’s Raised 2026 Earnings Outlook Will Impact IDEXX Laboratories (IDXX) Investors

IDEXX Labs Is Maintained at Neutral by UBS

UBS has maintained its "Neutral" rating on IDEXX Labs (IDXX) stock. This indicates that the analyst believes the stock will perform in line with the market. No specific financial data or price targets were provided in this brief announcement.

IDEXX Laboratories 2026: Revenue $1.22B, EPS $4.27— 10-Q Summary

IDEXX Laboratories reported strong financial results for the quarter ended 2026, with revenue of $1.22 billion and diluted EPS of $4.27, both exceeding the prior year. The growth was driven by higher volumes and prices in core segments, particularly recurring diagnostics and reference lab …

Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792

Jefferies has increased its price target for IDEXX Laboratories (IDXX) to $795 from the previous $792, while maintaining a Hold rating on the stock. This adjustment reflects a modest change in the firm's outlook for the company.

Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650

Citigroup has raised its price target for IDEXX Laboratories (IDXX) from $650 to $670, as reported on August 5, 2026. This adjustment follows other recent analyst updates for the company, including Jefferies increasing its target to $795 and UBS raising its target to $670. …

UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670

UBS has reiterated its Hold rating on IDEXX Laboratories Inc (IDXX.US) and increased its price target to $670. This adjustment reflects the firm's updated valuation for the company.

IDEXX Laboratories, Inc. Stock 12‑Month Price Target Raised to $719, Implies 27% Upside

Analysts have raised the average 12-month price target for IDEXX Laboratories, Inc. (IDXX) stock to $719, up from $711.64, with a range between $620 and $805. This new target suggests a potential upside of approximately 27% from its Aug. 3 closing price. The consensus …

IDEXX (IDXX) Stock Rewards Margin Strength And Recurring Diagnostics Growth

William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating

William Blair has reiterated its Buy rating on IDEXX Laboratories Inc (IDXX.US). This continued endorsement reflects a positive outlook from the firm regarding the company's performance and prospects.

IDEXX Laboratories (NASDAQ: IDXX) lifts Q2 2026 profit and cash flow

IDEXX Laboratories jumps 5% on strong results, raised guidance (IDXX:NASDAQ)

IDEXX Laboratories (IDXX) shares rose over 5% after the company reported strong second-quarter results and provided upbeat full-year earnings guidance. The veterinary diagnostics company posted an adjusted EPS of $4.07 for the quarter. This positive performance has led to a significant increase in its …